TXG

10X Genomics

$59.10

-4.75%
Nov 12, 2026
Bobby Quantitative Model
10x Genomics is a life science technology company that designs and sells integrated instruments, consumables, and software for single-cell and spatial biology research, spanning its Chromium, Chromium X, Visium, and Xenium platforms used by academic, translational, and biopharma customers worldwide. The company occupies a distinctive position as the leading pure-play platform provider in single-cell and spatial transcriptomics, monetizing a razor-and-blades model in which consumables generate the overwhelming majority of revenue while instruments seed future pull-through. The current investor narrative has shifted dramatically from a multi-year post-COVID research-spending slump toward a recovery-and-profitability story, with the stock up several-fold over the past year as investors position for a consumables-led reacceleration and improving operating leverage. Debate now centers on whether the recent rally is justified by durable demand for spatial platforms like Xenium, whether the company can cross into sustained GAAP profitability, and how competitive and patent litigation dynamics (including the recent Parse Biosciences verdict) affect the long-term moat.

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Moderna

Moderna

MRNA

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis

BobbyInvestment Opinion: Should I buy TXG Today?

Rating: Hold, with a constructive bias. The thesis is that 10x Genomics is a high-quality razor-and-blades franchise (consumables were $134.3M of $150.7M in Q3 2026 revenue, ~89%) whose gross margin has expanded ~765bp YoY to 74.95% and which generates $93.8M of TTM free cash flow, but whose top line has flatlined at ~$150M per quarter (+1.1% YoY) and which remains GAAP-unprofitable at -$19.4M. The analyst consensus of "buy" (6 Buy, 11 Hold, 0 Sell, mean 2.35) with a $69.57 average target implies only ~+17% upside from $59.28, and the 11 Hold ratings show the sell-side wants proof of reacceleration before turning positive.

Supporting evidence is mixed but tilts modestly positive on valuation and balance sheet. The PS ratio of 3.17x is far below the 78.4x and 116.1x levels seen historically, the PEG of 0.61 and price-to-book of 2.56 suggest little optimism is priced in, and gross margin of 69.1% TTM (74.95% latest quarter) is consistent with high-quality life science tools peers. Free cash flow is solidly positive at $93.8M TTM with $14.9M in Q3 2026, and the balance sheet is pristine — $526.2M cash, 4.46 current ratio, 0.198 debt-to-equity — so there is no dilution or solvency risk. Against that, revenue growth of +1.1% YoY, a forward PE of 683.97x on EPS of $0.325, and EV/EBITDA of 439.6x mean the current price already discounts a sharp earnings inflection that has not appeared in reported results.

The biggest risks that could invalidate the thesis are (1) the revenue plateau proving structural rather than cyclical — Q3 2026 revenue of $150.7M is below the $166.0M Q4 2025 peak, so sequential contraction is the pattern to watch; (2) multiple compression given a beta of 2.029 and a -40.6% max drawdown, with the -22.1% one-month decline already showing how fast sentiment can reverse; and (3) competitive and litigation overhang in single-cell and spatial biology, where the $4.8M Parse Biosciences verdict win was met with a 5% stock decline. This Hold would upgrade to Buy if quarterly revenue breaks above the $166.0M Q4 2025 peak with gross margin holding above 74%, or if the stock retraces toward the $50 low analyst target while fundamentals hold; it would downgrade to Sell if revenue falls below the ~$150M run-rate for another two quarters or gross margin slips back toward the 67.3% level of Q3 2025. On balance the stock looks fairly valued to modestly undervalued relative to its own history but expensive relative to current earnings — a show-me story rather than a compelling entry point at $59.28.

Sign up to view all

TXG 12-Month Price Forecast

The forward view is genuinely two-sided: the balance sheet ($526.2M cash, 0.198 debt-to-equity, 4.46 current ratio) and cash generation ($93.8M TTM FCF) remove the downside tail that usually accompanies unprofitable growth names, while the 3.17x PS multiple sits near the bottom of the stock's own historical band and the PEG of 0.61 suggests little optimism is priced in. Against that, revenue has been pinned near $150M for three consecutive quarters and is below the $166.0M Q4 2025 peak, so the 683.97x forward PE and 439.6x EV/EBITDA rest entirely on an earnings inflection that has not yet shown up in reported results. The -22.1% one-month drawdown after a +174.4% six-month run, combined with a 2.029 beta and -40.6% max drawdown, means the path to any re-rating will be violent in both directions. I would upgrade to bullish if quarterly revenue clears the $166.0M Q4 2025 peak with gross margin above 74%, and downgrade to bearish if revenue stays below $150M for another two quarters or gross margin retreats toward 67%. At $59.28 the risk/reward is roughly balanced, which is why the stance is neutral rather than directional.

Historical Price
Current Price $59.10
Average Target $67.50
High Target $100.00
Low Target $45.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on 10X Genomics's 12-month outlook, with a consensus price target around $68.14 and implied upside of +15.3% versus the current price.

Average Target

$68.14

17 analysts

Implied Upside

+15.3%

vs. current price

Analyst Count

17

covering this stock

Price Range

$50 - $100

Analyst target range

Buy
6 (35%)
Hold
11 (65%)
Sell
0 (0%)

Coverage is solid with 14 analysts, and the distribution of 6 Buy, 11 Hold, and 0 Sell ratings yields a consensus recommendation of "buy" with a recommendation mean of 2.35 (where lower is more bullish), indicating a cautiously constructive but not enthusiastic stance. The average target price of $69.57 implies roughly +17% upside from the current $59.28, a meaningful but not dramatic expected return that is consistent with a stock that has already rallied enormously and where analysts see limited near-term re-rating. The consensus leans mildly bullish on rating but the heavy Hold weighting signals that most analysts want to see evidence of revenue reacceleration before turning more positive.

The target range of $50.00 to $100.00 is wide — a 2x spread from low to high — signaling high uncertainty and genuine disagreement about the trajectory. The $100 high target likely assumes a return to double-digit growth, successful spatial platform adoption, and multiple expansion back toward prior levels, while the $50 low target prices in continued revenue stagnation, competitive pressure, and margin compression. Institutional ratings show a stable pattern of reiterations rather than upgrades or downgrades — Stifel maintaining Buy, TD Cowen and Morgan Stanley holding at Hold/Equal Weight, Barclays at Overweight — suggesting analysts are in a wait-and-see posture. The wide spread combined with the recent -22% one-month drawdown implies elevated volatility and less efficient price discovery, so investors should treat the consensus target as a directional signal rather than a precise price objective.

Drowning in data?

Find the real signal!

Bulls vs Bears: TXG Investment Factors

The bear case currently has the stronger near-term evidence: revenue is flat at roughly $150M per quarter with +1.1% YoY growth, GAAP losses persist at -$19.4M, and the stock has surrendered 22.1% in a month after a 174.4% six-month run. The bull case rests on genuine but forward-looking improvements — gross margin up to 74.95%, positive $93.8M TTM free cash flow, a pristine balance sheet with $526.2M cash and 0.198 debt-to-equity, and a 3.17x PS multiple near multi-year lows. The single most important tension is whether the revenue plateau is a cyclical trough in research spending or a new normal: if consumables pull-through reaccelerates, the depressed multiple and expanding margins make the stock look cheap, but if $150M per quarter is the new baseline, the 683.97x forward PE has no earnings support. Analyst positioning (6 Buy, 11 Hold, 0 Sell, $69.57 average target) captures this standoff precisely — constructive on direction, unconvinced on timing.

Bullish

  • Gross margin expansion signals operating leverage: Gross margin rose from 67.3% in Q3 2025 to 74.95% in Q3 2026, a roughly 765bp improvement achieved even as revenue grew only +1.1% YoY. This cost discipline is flowing through: the quarterly net loss narrowed from -$34.4M in Q1 2025 to -$19.4M in Q3 2026, and TTM free cash flow is solidly positive at $93.8M.
  • Valuation near multi-year lows: The PS ratio of 3.17x sits far below the 78.4x and 116.1x levels seen in prior periods, placing the stock near the bottom of its own historical valuation band. With a PEG of 0.61 and price-to-book of 2.56, the market is pricing in very little optimism about a revenue recovery.
  • Fortress balance sheet funds the turnaround: Debt-to-equity is just 0.198 and the current ratio is 4.46, backed by $526.2M in cash at Q3 2026. The company is self-funding $52.9M of quarterly R&D from internal resources, so there is no dilution or liquidity overhang threatening the recovery thesis.
  • Analyst consensus still constructive: Coverage of 14 analysts yields 6 Buy, 11 Hold and 0 Sell ratings, with an average target of $69.57 implying roughly +17% upside from $59.28. The complete absence of Sell ratings despite a -22.1% one-month drawdown suggests the sell-side views the pullback as a shakeout rather than a broken thesis.

Bearish

  • Revenue has flatlined at ~$150M: Quarterly revenue was $150.8M in Q1, $151.0M in Q2 and $150.7M in Q3 2026, with YoY growth of only +1.1%. Worse, this is below the $166.0M posted in Q4 2025, indicating the business is contracting sequentially from its recent peak rather than merely pausing.
  • Still deeply unprofitable on a GAAP basis: Q3 2026 net income was -$19.4M (-12.9% net margin) and operating income was -$16.1M (-10.7% operating margin), weighed down by $76.1M in G&A/SG&A and $52.9M in R&D. The forward PE of 683.97x on EPS of $0.325 requires a dramatic earnings inflection that has not yet appeared in reported results.
  • Extreme volatility and momentum breakdown: Beta of 2.029 means the stock moves roughly twice the market, and the -40.6% max drawdown confirms that risk in practice. The 1-month change of -22.1% against a +174.4% six-month gain is a classic parabolic unwind, with relative strength versus the S&P 500 at -17.1% over one month.
  • Wide analyst dispersion signals uncertainty: Targets range from $50 to $100, a 2x spread, and 11 of 14 analysts rate the stock a Hold with a recommendation mean of 2.35. This is a wait-and-see consensus, not conviction — most analysts want evidence of reacceleration before upgrading, leaving limited near-term re-rating support.

TXG Technical Analysis

10x Genomics is in a powerful, sustained uptrend that has dramatically reversed its prior downtrend, with a 1-year price change of +356.0% and a year-to-date gain of +256.7%. At the current price of $59.28, the stock sits roughly 49% of the way through its 52-week range of $15.12 to $102.81, meaning it has surrendered a large portion of its earlier advance but remains far above its lows. That positioning signals a stock in a high-volatility momentum phase that has already broken down from its peak rather than one pressing against new highs, leaving it in a contested middle zone where both trend continuation and deeper mean reversion are plausible.

Short-term momentum has deteriorated sharply even as the longer-term trend remains strongly positive, creating a clear divergence. The 1-month change is -22.1% versus a 3-month gain of +13.9% and a 6-month gain of +174.4%, and relative strength versus the S&P 500 is -17.1% over one month against +346.4% over one year. This pattern — a parabolic multi-month advance followed by a violent one-month pullback — is characteristic of momentum unwinding and profit-taking after an overextended run rather than a clean trend reversal, though the magnitude of the drawdown (a max drawdown of -40.6%) underscores how fragile the recent rally structure has become. Volume of roughly 4.5 million shares and a short ratio of 3.09 suggest active two-way trading with meaningful short interest that can amplify moves in either direction.

Key technical levels are well defined: support sits near the 52-week low of $15.12, with intermediate support implied by the recent November lows around $58, while resistance is anchored at the 52-week high of $102.81 and the prior breakout zone near $97. A decisive reclaim of the $80–$90 area would signal the pullback was a shakeout and reassert the uptrend, whereas a break below the $58 area would confirm a deeper correction toward the mid-$40s. With a beta of 2.029, the stock is roughly twice as volatile as the market, meaning position sizing and stop discipline are critical — a 2x beta implies drawdowns can be roughly double the broader market's in risk-off periods, consistent with the -40.6% max drawdown observed.

Beta

2.03

2.03x market volatility

Max Drawdown

-40.6%

Largest decline past year

52-Week Range

$15-$103

Price range past year

Annual Return

+254.1%

Cumulative gain past year

PeriodTXG ReturnS&P 500
1m-17.7%-2.7%
3m+5.4%-2.5%
6m+178.8%+2.4%
1y+254.1%+10.8%
ytd+255.6%+11.0%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

TXG Fundamental Analysis

Revenue growth has decelerated to a near-standstill, with the most recent quarter (Q3 2026) posting revenue of $150.7 million and year-over-year growth of just +1.1%, a sharp contrast to the double-digit growth the company once delivered. The multi-quarter trend shows revenue essentially flat sequentially — $150.8 million in Q1, $151.0 million in Q2, and $150.7 million in Q3 2026 — indicating a plateau rather than an accelerating trajectory, and notably below the $166.0 million reported in Q4 2025. Segment data confirms the mix is overwhelmingly consumables-driven, with consumables at $134.3 million versus instruments at just $6.9 million and services at $9.0 million, meaning the entire growth equation hinges on consumable pull-through per installed system rather than new instrument placements.

Profitability remains elusive on a GAAP basis, though the loss trajectory is improving. Q3 2026 net income was -$19.4 million (a -12.9% net margin) with gross margin of 74.95%, and the quarterly loss has narrowed from -$34.4 million in Q1 2025 to the current level, while gross margin has expanded from 67.3% in Q3 2025 to 74.95% in Q3 2026. Operating income remains negative at -$16.1 million (a -10.7% operating margin), weighed down by $52.9 million in R&D and $76.1 million in G&A/SG&A, but the improving gross margin and shrinking net loss suggest operating leverage is beginning to materialize even as revenue stalls.

The balance sheet is a clear strength: debt-to-equity is just 0.198, the current ratio is a robust 4.46, and cash at the end of Q3 2026 stood at $526.2 million. Free cash flow is solidly positive at $93.8 million on a trailing-twelve-month basis, with quarterly FCF of $14.9 million in Q3 2026, and ROE of -5.5% and ROA of -3.9% reflect the modest GAAP losses rather than any liquidity stress. The company is self-funding its growth and R&D internally from a deep cash pile, meaning financial risk is low and the primary risk is execution on reaccelerating revenue rather than balance-sheet fragility.

Quarterly Revenue

$150667000.0B

2026-09

Revenue YoY Growth

+1.1%

YoY Comparison

Gross Margin

75.0%

Latest Quarter

Free Cash Flow

$93771000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Consumables
Instruments
Licensing And Royalty Revenue
Product And Service Revenue
Service

Open an Account, get $2 TSLA now!

Valuation Analysis: Is TXG Overvalued?

Because trailing net income is negative (EPS of -$0.02 and a trailing PE of -46.6), the PE ratio is not meaningful, so the appropriate primary metric is the price-to-sales ratio, which stands at 3.17x on a market cap of roughly $2.03 billion against a revenue base near $600 million annualized. The forward PE of 683.97x and forward EPS estimate of $0.325 imply the market expects a dramatic swing to profitability, and the enormous gap between the negative trailing PE and the triple-digit forward PE reflects expectations of an earnings inflection rather than current fundamentals. The EV/Sales multiple of 11.73x and EV/EBITDA of 439.6x further underscore that valuation is being driven by future growth and margin recovery rather than present cash generation.

On a relative basis, the 3.17x PS ratio is modest for a life science tools platform company and sits well below the company's own historical norms, while the PEG ratio of 0.61 and price-to-book of 2.56 suggest the market is not paying a rich premium for growth at current levels. The gross margin of 69.1% (and 74.95% in the latest quarter) is consistent with high-quality life science tools peers, supporting the argument that the current multiple embeds skepticism about the revenue plateau rather than enthusiasm. The premium-versus-discount question hinges on whether the flat +1.1% revenue growth is a trough or a new normal — if growth reaccelerates, the current multiple looks inexpensive; if stagnation persists, it is fair to full.

Historical context is striking: the PS ratio has collapsed from 78.4x in Q3 2026 historical data and 116.1x back in Q4 2021 to the current 3.17x, placing the stock near the very bottom of its own multi-year valuation band. That compression reflects both the post-2021 de-rating of high-growth life science names and the revenue slowdown, and it means the market is pricing in very little optimism. Near historical lows can signal either a genuine value opportunity if fundamentals stabilize or continued fundamental deterioration if the revenue plateau persists — the improving gross margins and positive free cash flow tilt the evidence modestly toward the former.

PE

-46.6x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

29.3x

Industry PE ~29.3x*

EV/EBITDA

439.6x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the stalled top line and persistent GAAP losses. Revenue has been pinned near $150M for three consecutive quarters (+1.1% YoY in Q3 2026) and sits below the $166.0M Q4 2025 peak, so the entire growth equation depends on consumable pull-through from an installed base that is not visibly expanding — instruments contributed only $6.9M of quarterly revenue. Operating income remains -$16.1M (-10.7% margin) with $52.9M of quarterly R&D and $76.1M of G&A/SG&A, meaning the company must hold spending flat while waiting for a demand recovery. The mitigating factor is balance-sheet strength: $526.2M cash, a 4.46 current ratio, 0.198 debt-to-equity and $93.8M TTM free cash flow mean there is no solvency or dilution risk, so the financial risk is one of earnings disappointment rather than liquidity stress.

Market and competitive risks are dominated by valuation sensitivity and extreme price volatility. With a beta of 2.029, TXG amplifies market moves roughly twofold, and the -40.6% max drawdown demonstrates how violent the downside can be; the -22.1% one-month decline against a -4.99% S&P 500 move produced -17.1% relative underperformance in just four weeks. The forward PE of 683.97x and EV/EBITDA of 439.6x leave no room for execution error — any quarter that fails to show revenue reacceleration risks multiple compression toward the $50 low analyst target. Competitive and legal dynamics add noise: the $4.8M patent verdict against Parse Biosciences was a win, yet the stock fell 5% on the news, showing the market is focused on legal costs and competitive encroachment in single-cell and spatial biology rather than courtroom victories.

The worst-case scenario is a confirmed demand plateau combined with a growth-multiple de-rating. If Q4 2026 revenue fails to break above the $150M run-rate and management guides conservatively, the 11 Hold-rated analysts would likely capitulate, pushing the stock toward the $50 low target — a roughly -16% decline from $59.28. A harsher outcome, where research-spending weakness persists and the market re-prices the stock as a no-growth tools company, would take shares back toward the November lows near $58 and potentially the mid-$40s implied by technical support, a -22% to -25% move. In a genuine risk-off dislocation, the 52-week low of $15.12 represents a -74% tail scenario, though the positive free cash flow and $526.2M cash pile make that outcome unlikely absent a fundamental collapse.

FAQ

The most severe risk is fundamental: revenue has flatlined at roughly $150M per quarter for three consecutive quarters (+1.1% YoY) and sits below the $166.0M Q4 2025 peak, so if the plateau is structural rather than a cyclical research-spending trough, the growth case collapses and the 683.97x forward PE has no earnings support. Second is valuation and volatility risk — with a beta of 2.029 and a -40.6% max drawdown, the stock amplifies market moves roughly twofold, and the -22.1% one-month decline against a -4.99% S&P 500 move produced -17.1% relative underperformance in just four weeks, showing how quickly sentiment reverses after a +174.4% six-month run. Third is profitability risk: operating income remains -$16.1M (-10.7% margin) with $52.9M of quarterly R&D and $76.1M of G&A/SG&A, so the company must hold spending flat while waiting for demand, and any gross margin retreat from 74.95% toward the 67.3% Q3 2025 level would undercut the operating-leverage narrative. Fourth is competitive and litigation overhang in single-cell and spatial biology — the $4.8M patent verdict against Parse Biosciences was a legal win yet the stock fell 5%, reflecting skepticism about near-term financial impact and ongoing legal costs. Ranked by severity: revenue plateau first, multiple compression/volatility second, margin durability third, litigation and competition fourth.

The 12-month outlook splits into three scenarios with a 50/25/25 probability weighting. The base case (50%) targets $60–$75, assuming revenue grinds modestly higher from the ~$150M quarterly run-rate, gross margin holds in the low-to-mid 70s, free cash flow stays near the $93.8M TTM level, and the stock trades around the $69.57 average analyst target supported by the 3.17x PS multiple but capped by the lack of earnings. The bull case (25%) targets $85–$100, requiring consumables pull-through to reaccelerate, quarterly revenue to break above the $166.0M Q4 2025 peak toward the $231M implied by the $924.6M analyst revenue estimate, gross margin near 75%, and upgrades from the 11 Hold-rated analysts toward the $100 high target. The bear case (25%) targets $45–$55, in which the plateau proves structural, management guides conservatively, and multiple compression on a 2.029-beta stock takes shares toward the $50 low target and the mid-$40s. The base case is most likely, and its key assumption is that the revenue plateau is a cyclical trough rather than a new normal — the single variable that most changes the forecast.

The answer depends heavily on which metric you anchor to, and the two tell opposite stories. On trailing earnings the stock is effectively unvaluable — trailing EPS is -$0.02, the trailing PE is -46.6, and EV/EBITDA is 439.6x — while the forward PE of 683.97x on estimated EPS of $0.325 implies the market expects a dramatic swing to profitability that has not shown up in reported results. On sales, however, the 3.17x PS ratio looks inexpensive for a life science tools platform with 69.1% TTM gross margin (74.95% in the latest quarter), and it is dramatically below the 78.4x and 116.1x levels the stock commanded historically, reflecting both the post-2021 de-rating of high-growth life science names and the revenue slowdown. Price-to-book of 2.56 and a PEG of 0.61 reinforce that little optimism is embedded at current levels. What the valuation implies is that the market is pricing the +1.1% revenue growth as a durable new normal rather than a cyclical trough — if consumables pull-through reaccelerates, the multiple looks cheap; if stagnation persists, it is fair to full. Net, the stock looks fairly valued to modestly undervalued relative to its own history but expensive relative to current earnings.

The risk/reward at $59.28 is roughly balanced rather than compelling. On the positive side, the $69.57 average analyst target implies about +17% upside, the 3.17x PS ratio sits near the bottom of the stock's own multi-year band (versus 78.4x and 116.1x historically), the PEG of 0.61 suggests little optimism is priced in, and the balance sheet — $526.2M cash, 0.198 debt-to-equity, 4.46 current ratio — removes solvency and dilution risk while $93.8M of TTM free cash flow funds operations internally. On the negative side, revenue has been pinned near $150M for three straight quarters (+1.1% YoY) and is below the $166.0M Q4 2025 peak, GAAP net income is still -$19.4M, and the 683.97x forward PE means the price already assumes an earnings inflection. The biggest downside risk is a confirmed structural plateau, which would likely pull shares toward the $50 low target (about -16%) and potentially the mid-$40s in a risk-off tape given the 2.029 beta. It is a reasonable buy for risk-tolerant investors with a multi-year horizon who want exposure to a consumables-led recovery and can size positions for a -40.6% historical max drawdown; it is not attractive for conservative or income-oriented investors, and waiting for one quarter of revenue above $166.0M would materially improve the odds.

TXG is structurally a long-term holding candidate but a poor short-term trading vehicle for most investors. The company is in a late-stage growth transition — revenue near $600M annualized, 89% consumables mix, gross margin of 74.95% in the latest quarter, and positive $93.8M TTM free cash flow — but it remains GAAP-unprofitable with a 683.97x forward PE, meaning the payoff depends on a multi-quarter reacceleration that will not resolve quickly. Volatility argues strongly against short-term positioning: beta of 2.029, a -40.6% max drawdown, a -22.1% one-month move after a +174.4% six-month run, and a short ratio of 3.09 all mean near-term price action is driven by momentum and sentiment rather than fundamentals. There is no dividend (0% yield, 0% payout), so there is no income component to hold for, and earnings visibility is low given the flat top line. A concrete suggested minimum holding period is 18–24 months, long enough to span four to six quarterly prints and observe whether revenue clears the $166.0M Q4 2025 peak and whether GAAP operating income turns positive; position sizing should reflect the roughly 2x market volatility, and investors unwilling to tolerate a -40% drawdown should avoid the name.